Loading clinical trials...
Loading clinical trials...
A Phase 2 Randomized, Double-Blind, Multicenter Trial of Amplimexon® Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy Naïve Pancreatic Adenocarcinoma (Stage IV)
Conditions
Interventions
imexon in combination with gemcitabine
imexon placebo + gemcitabine
Locations
48
United States
Birmingham Hematology and Oncology- US Oncology
Birmingham, Alabama, United States
AZ Onc Associates D.B.A. Hematology Oncology- US Oncology
Tucson, Arizona, United States
Arizona Clinical Research Center
Tucson, Arizona, United States
Rocky Mountain Cancer Center- US Oncology
Denver, Colorado, United States
Ocala Oncology Center- US Oncology
Ocala, Florida, United States
Cancer Centers of Florida- US Oncology
Orlando, Florida, United States
Start Date
April 1, 2008
Primary Completion Date
May 1, 2010
Completion Date
June 1, 2010
Last Updated
March 20, 2019
NCT07542041
NCT03937453
NCT06885697
NCT04146298
NCT06388967
NCT04291651
Lead Sponsor
AmpliMed Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions